Pharmacotherapy: Pasireotide for uncontrolled acromegaly—new phase III trial data


Results from a phase III clinical trial show that pasireotide long-acting release (LAR) is more effective than either octreotide or lanreotide for treating patients with acromegaly, supporting use of pasireotide LAR for patients with disease that is inadequately controlled by first-generation somatostatin analogues. Octreotide and lanreotide are the current… (More)
DOI: 10.1038/nrendo.2014.176


  • Presentations referencing similar topics